With so many heart medications on the market right now, it can get confusing as to what is the best treatment for atrial fibrillation. The newer medications like Rivaroxaban, apixaban and dabigatran are currently being given the nod of being a better (and some even say safer) treatment than the ever-popular warfarin, but that can leave some wondering if Multaq is even worth being posted in the same category as they are.

Multaq (dronedarone), made by Sanofi-Aventis, works much like the other medications in that it seeks to prevent strokes while helping to appease the fluttering heart rhythms that AF is characterized by. The drug was originally approved as a treatment for temporary AF. When Multaq was put through a clinical trial to see if it could handle permanent AF, the study had to be stopped after patients started dying and experiencing a worsening of their heart conditions.

Once the study (referred to as the PALLAS study) was halted, Multaq started getting reviewed more to see if it was safe to use at all. In the end, the FDA recommended that Multaq only be used as a last-ditch effort should other drugs prove to be unhelpful. Catheter ablations have also gained in popularity as all of these medications cause their own side effects, but many patients prefer the medication to the ablation procedure.

Aside from the worsening of heart conditions, Multaq has also been linked to liver failure. These serious side effects from Multaq, when pit against other medications, catheter ablations, freezing and heat treatments, are all making Multaq sound almost archaic in comparison. Some even believe that Multaq will soon be on its way out of the market in favor of safer drugs and treatments.

If you or a loved one has suffered from liver failure, or a worsening of your heart condition after taking Multaq, you will want to have a free consultation with the attorneys at Greg Jones. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.